Active ingredientPlazomicinCat. No. P-P146-001CAS 1154757-24-0Family · Pharmaceutical analytical standards
Plazomicin
A next-generation aminoglycoside derived from sisomicin, approved in the United States in 2018 for complicated urinary tract infections, including pyelonephritis, when few alternatives remain: it curbs bacterial protein production. This family brings together the active ingredient and nitrosamines.
Did you know?A small hydroxyethyl group added to the molecule makes it immune to acetylation by AAC(6')-Ib, the most widespread of the acetylating enzymes bacteria use to inactivate aminoglycosides.
Go to the active ingredient →Active ingredientPlazomicinCat. No. P-P146-001CAS 1154757-24-0
NitrosamineN1-Nitroso PlazomicinCat. No. P-P146-002
NitrosamineN2-Nitroso PlazomicinCat. No. P-P146-003No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.